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ABSTRACT
Objectives: The effect of exogenous progesterone on fetal nuchal translucency (NT) has been proposed recently. In this study, 
we aimed to compare the thickness of NT of patients receiving and not receiving progesterone for threatened miscarriage.
Material and methods: This study was designed as a retrospective comparative study. Ninety five women treated with 
progesterone constituted the study group whereas 97 women who were not treated with progesterone constituted the 
control group. An ultrasonographic examination was performed on all of the women to measure NT. All patients were treated 
with oral micronized progesterone in the study group. The main parameters recorded for each woman were; age, body 
mass index (BMI), obstetrical characteristics, and gestational age at first examination, treatment duration of progesterone 
therapy, and results of combined and triple tests.
Results: A total of 192 pregnant women with threatened miscarriage were included in this study. The mean NT thickness 
was statistically significantly higher in the study group (p < 0.001), and mean serum level of human chorionic gonadotropin 
(hCG) was also higher in this group (p < 0.05). There was no statistically significant difference between groups in terms of 
age, BMI, and gestational age at first examination. ROC curve analysis demonstrated that only increased NT (area under the 
curve: 0.634, p = 0.005, 95% CI: 0.541–0.727) was a discriminative factor for women receiving progesterone for threatened 
miscarriage. Also there was a positive correlation between NT and treatment duration (r = 0.269; p < 0.001).
Conclusions: We think that oral progesterone therapy may increase NT depending on treatment duration without causing 
abnormal prenatal screening test results.
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INTRODUCTION
Prenatal screening tests first appeared in the mid-1970s, 
with the use of maternal serum alpha-fetoprotein (AFP) levels 
for neural tube defects [1]. Then, the concept of the multiple 
of the median (MoM) value was proposed to standardize in-
ter-laboratory variations and factors that may affect the serum 
AFP level, e.g. gestational age [2]. Obviously, pregnancies with 
certain fetal aneuploidies will cause psychological and finan-
cial loss in the affected families and communities. Therefore, 
various non-invasive screening tests have been developed 
for early detection and termination of these pregnancies, 
without harming the mother. Wald et al. [3], combined AFP, 
unconjugated estriol (E3), and human chorionic gonadotropin 
(hCG) with maternal age to produce an estimate of the risk of 
having a Down syndrome pregnancy, and they called it the 
‘triple test’. This screening tool has been widely used all over 
the world until the end of the 90s. 
Serum levels of pregnancy-associated plasma pro-
tein-A (PAPP-A) and free β-hCG show significant changes in 
the mothers of aneuploid fetuses [4]. Increased thickness of 
fetal nuchal translucency (NT), defined as a transient fluid 
collection behind the fetal neck and visible on ultrasound 
at the end of the first trimester, is also a sensitive marker of 
fetal aneuploidy [5]. The combined first-trimester screening, 
which includes all of these parameters, was popular in the 
2000s. Later, different risk assessment tests and integrated 
tests have been proposed. In the end, cell-free fetal nucleic ac-
ids in maternal serum have proceeded to take their place [6].
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Abortion is a spontaneous loss of a fetus < 20 weeks 
of gestation. It is a traumatic event, which can have psy-
chological consequences for the parents [7]. Threatened 
miscarriage, demonstrated by vaginal bleeding with or 
without abdominal cramps, is a common complication of 
early pregnancy. It occurs in about a fifth of all pregnancies 
and approximately half of them will be lost. Progesterone 
is an essential hormone for the continuation of pregnancy 
and is prescribed in 13–40% of women with threatened 
miscarriage, according to the literature [8]. Some authors 
suggested that progesterone reduced the abortion rate 
in women with threatened miscarriage [7]. Progesterone 
shows these effects by releasing certain anti-abortive cy-
tokines, modulation of the maternal immune system (im-
munological tolerance of the fetus), and with relaxation of 
uterine muscles [9]. Data on the use of progesterone for 
threatened miscarriage remain conflicting. A more recent 
systematic review suggested lack of evidence to support 
routine use of progesterone to prevent miscarriage in early 
to mid-pregnancy [10].
Recently, Giorlandino et al. [11], speculated that exog-
enous progesterone use could lead to abnormal blood flow 
pattern, which in turn may affect fetal development in the 
first trimester. Also, they concluded that exogenous pro-
gesterone increases NT. In our study, we aimed to compare 
the NT thickness of patients receiving and not receiving 
progesterone for threatened miscarriage, and evaluate the 
results of the prenatal screening test.
MATERIAL AND METHODS
We designed a retrospective study of patients with 
threatened miscarriage. Local Ethics Committee approved 
of the study. The archives of our early pregnancy and emer-
gency units were searched to identify patients who met 
the criterion of vaginal bleeding and were diagnosed with 
threatened miscarriage in the early first trimester between 
January 2013 and December 2013. This is a tertiary refer-
ral research and education hospital located in the capital 
city of Turkey, Ankara. Informed consent was not obtained 
due to retrospective design of the study. The inclusion cri-
teria for the entire cohort were as follows: maternal age 
of 18–40 years, diagnosis of threatened miscarriage, BMI 
of < 30 kg/m2 at diagnosis, non-smoker, no history of 
co-morbidities or medications other than progesterone, 
and an ultrasound test performed between 110 to 13+6 and 
150 to 19+6 weeks of gestation with antenatal screening test 
results. We excluded patients with recurrent miscarriage, 
intrauterine fetal exitus, major fetal malformation, uterine 
anomaly, multiple pregnancies, and after assisted repro-
ductive techniques. We also excluded patients who had 
incomplete laboratory data and had no available medical 
records or ultrasound reports.
Patients were subdivided into the study group (proges-
terone treated) and controls (non-treated) based on whether 
they received progesterone treatment. Patients who were 
treated with oral micronized progesterone (Progestan®, 
Natural Micronized Progesterone, Koçak Farma, Turkey) were 
identified on the basis of patient files or the official prescrip-
tion record system. A 300 mg dose of orally administered 
micronized form per day, a dose regimen recommended by 
pharmaceutical companies, was considered as standard. All 
patients from the study group had used progesterone for 
at least 10 days.
A careful physical and pelvic examination was per-
formed in all patients after the initial evaluation, which 
included obstetric and general history. It was recorded that 
all pregnancies continued beyond 20 weeks of gestation. We 
also confirmed that all NT measurements were performed 
by certified expert radiologists and/or gynecologists of our 
institution using a General Electric Logiq A5 (Milwaukee, 
USA) convex probe (3.5  Hz) or transvaginal probe (5  Hz). 
The CRL lengths were kept between 45 to 84 mm for NT 
measurements. 
The evaluated clinical and laboratory characteristics 
included: age, BMI, gravidity, parity, number of abortions, 
smoking status, comorbidities, additional medications, ges-
tational week at diagnosis, progesterone therapy duration, 
and results of the combined and triple tests, including MoMs 
of PAPP-A, free β-hCG, AFP, E3, and hCG.
Statistical analysis
Statistical analysis was carried out using statistical pack-
ages for SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA). 
Mean and standard deviation (SD) were calculated for con-
tinuous variables. Chi-square (χ2) test and Independent 
Samples t-test evaluated the associations between categori-
cal and continuous variables. Non-normally distributed cat-
egorical variables were evaluated by Mann-Whitney U test. 
Pearson correlation analysis was used to assess correla-
tions between the clinical parameters. ROC curve analysis 
was used to find the discriminative factors between the 
groups. Two-sided P values were considered as statistically 
significant at p < 0.05. 
RESULTS
A total of 192 pregnant women with threatened miscar-
riage were included in this retrospective comparative study. 
Ninety-five women treated with progesterone constituted the 
study group, whereas 97 women who were not treated with 
progesterone constituted the control group. Table 1 shows 
the comparison of cases between the two groups with regard 
to the demographic and clinical characteristics. Statistically 
significant differences were noted in median gravidity be-
tween the groups (p = 0.041). Mean gestational age at the 
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initial diagnosis was 8.0 ± 1.7 and 8.4 ± 1.8 weeks in the study 
and control groups, respectively (p = 0.101). Mean duration 
of treatment was 3.9 ± 1.6 weeks in the progesterone-treated 
group. Mean MoM value of the NT thickness was statistically 
significantly higher in the study group, and mean serum levels 
of free β-hCG and hCG were also higher in this group (p < 0.05) 
(Table 2). The results of the risk assessment in both, combined 
and triple test, revealed no statistically significant differences 
between the two groups (Table 3). When all variables were 
included in the ROC curve analysis, it was demonstrated that 
only NT, hCG, and free β-hCG (AUC: 0.666, p < 0.001, 95% 
CI: 0.587–0.742; AUC: 0.636, p = 0.001, 95% CI: 0.557–0.716, 
AUC: 0.600, p = 0.015, 95% CI: 0.519–0.681, respectively) were 
discriminative factors for women receiving progesterone for 
Table 1. Comparison of cases between two groups according to the demographic and clinical characteristics
Progesterone-treated group (n: 95) Control group (n: 97) P value
Age (years) 25.8 ± 5.5 26.4 ± 4.6 0.139
Gravidity 2 (1–6) 2 (1–4) 0.041
Parity 1 (0–3) 0 (0–2) 0.100
Spontaneous abortion 0 (0–3) 0 (0–2) 0.238
Elective abortion 0 (0–2) 0 (0–1) 0.541
Children alive 1 (0–3) 0 (0–2) 0.508
Gestational week 8.0 ± 1.7 8.4 ± 1.8 0.101
Initial week 8.0 ± 1.7
Treatment duration (weeks) 3.9 ± 1.6
Data are presented as mean ± SD and median (min-max). p < 0.05 is considered statistically significant
Table 2. Distribution of MoM values in two groups
Progesterone-treated group (n: 95) Control group (n: 97) P value
PAPP-A 1.04 ± 0.73 1.13 ± 0.88 0.388
NT 1.13 ± 0.42 0.91 ± 0.29 < 0.001
Free-hCG 1.14 ± 0.66 1.03 ± 0.76 0.015
E3 0.97 ± 0.38 0.97 ± 0.55 0.525
AFP 1.06 ± 0.47 0.94 ± 0.35 0.146
hCG 1.17 ± 0.37 1.01 ± 0.41 0.007
Data are presented as mean ± SD, and values were expressed as multiple of median (MoM). P < 0.05 is considered statistically significant. PAPP-A — pregnancy-
associated plasma protein-A, E3 — estriol, hCG — human chorionic gonadtropin, AFP — alfa-feto protein, NT — fetal nuchal translucency
Table 3. Comparison of the prenatal assessment of risk of fetal aneuploidy
Progesterone-treated group (n: 95) Control group (n: 97) P value
Biochemical risk
< 1/50
1/50–1/100
1/100–1/250
> 1/250
 
0
1
2
91
 
0
2
1
93
0.615
Double risk
< 1/50
1/50–1/100
1/100–1/250
> 1/250
 
0
3
5
87
 
0
2
5
90
0.891
Combined risk
< 1/50
1/50–1/100
1/100–1/250
> 1/250
 
0
0
0
95
 
0
0
2
95
0.497
Data are presented as number
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threatened miscarriage (Figure 1). Also, there was a positive 
correlation between NT and treatment duration (r = 0.269; 
p < 0.001).
DISCUSSION
In our study, we intended to compare NT thickness of 
patients receiving and not receiving progesterone for threat-
ened miscarriage, and to evaluate whether oral progester-
one therapy increases NT thickness and causes abnormal 
antenatal screening test results. Our results revealed NT 
thickness to be higher in patients who were treated with oral 
progesterone. Also, this treatment does not cause abnormal 
antenatal screening test results.
Progesterone is a steroid hormone which plays a crucial 
role at each stage of pregnancy, and modulates mater-
nal immune response to prevent rejection of the embryo. 
Progesterone regulates the peri-implantation period and 
immune responses during pregnancy, but also suppresses 
uterine contractions during pregnancy, and initiates labor 
and cervical ripening at the end of pregnancy. In the hu-
man reproductive system, progesterone exerts its effects 
via genomic and non-genomic actions which converge to 
produce tissue- and cell-specific responses [12]. 
Trophoblastic invasion is strictly controlled by prote-
olytic enzymes such as matrix metalloproteinase (MMP) 
which digest extracellular matrix components, e.g. collagen. 
Progesterone acts as a regulator of trophoblast invasion 
by controlling MMP activity directly or indirectly via local 
mediators, e.g. cytokines [13].
Several studies have suggested that progesterone de-
creases spontaneous miscarriages and increases implanta-
tion rates. Although there is no evidence to support the 
routine use of progestagens for the treatment of threatened 
miscarriage, progestagens are often used in routine practice 
due to patient expectations to receive prescriptions. Also, 
the optimal route of administration and the dose regimen 
remain unclear. According to a limited number of meta-anal-
yses, it was suggested that progesterone, both in prevention 
or treatment of miscarriages, does not change the outcome 
of pregnancy. Data on the potential harms to the mother 
and/or the child connected with the use of progestagens 
are scant [14]. Therefore, the use of progesterone during the 
first trimester of pregnancy should be reserved to cases of 
assisted reproductive technology pregnancies, where the 
luteal phase is insufficient, and in cases of women at risk for 
preterm birth [15, 16].
It is universally known that hCG belongs to the family 
of glycoprotein hormones characterized by a heterodimeric 
structure, with the α and β-subunits. The function of hCG 
is still defined as ‘progesterone promotion’ in most medi-
cal textbooks, but we also know that hCG has numerous 
other important placental, uterine, and fetal functions in 
pregnancy. After embryo implantation, hCG starts to be 
produced by trophoblast and interacts with the LH (lutein-
izing hormone)/hCG receptor of the ovary and promotes the 
maintenance of the corpus luteal progesterone production. 
This continues for approximately 4 weeks. After that time, 
there are sufficient syncytiotrophoblast cells in the placenta 
to take over progesterone production from the corpus lu-
teum [17]. In a previous study performed with cultured 
human cells, it was shown that progesterone suppressed 
hCG secretion, and suppression of hCG by progesterone 
occurred in a dose-response manner [18]. Interestingly, 
we found higher serum hCG levels in women treated with 
progesterone in both, combined and triple test results. This 
situation may be due to differences in the risk of miscarriage 
or amount of bleeding.
Increased NT thickness may not always be associated 
with fetal chromosomal abnormalities. Although different 
proposals exist in the literature (e.g. cardiac dysfunction, 
venous congestion, and delayed or abnormal lymphatic 
drainage), the real pathophysiological mechanism remains 
to be fully elucidated [19]. On the other hand, the effect 
of progesterone has been attempted to be explained by 
hemodynamic disturbance that leads to fluid accumulation 
[11]. Regardless, we are of the opinion that progesterone 
may also increase the NT by changing the ultra-structure 
of the extracellular matrix.
To the best of our knowledge, this study has been one 
of the first to investigate the relation between progesterone 
therapy and NT thickness. A recent study by Giorlandino et 
al. [11], showed that exogenous progesterone therapy af-
fects fetal NT thickness regardless of progesterone content, 
dosage, and route of administration. These authors had 
important confounders, including gestational age, maternal 
age, BMI, smoking status in their large numbered prospec-
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Figure 1. ROC curve analysis of significant discriminants for the 
progesterone treated group
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tive study but they found a strong association between the 
use of progesterone and NT thickness in all the gestational 
ages considered, with a higher degree of significance at 
110 to 11+6 weeks of gestation after controlling these con-
founders. In our study, mean MoM of NT thickness was 
significantly higher in the progesterone-treated group, what 
was consistent with their report. Our study had several 
limitations, including its retrospective nature. Also, the pa-
tients were not divided into different categories according 
to their gestational weeks. Regardless, the groups were 
homogenously distributed, and we only included women 
who had threatened miscarriage and were treated with oral 
natural progesterone.
CONCLUSIONS
Our study confirms that oral progesterone therapy for 
threatened miscarriage in the first trimester may increase 
fetal NT thickness and may alter maternal serum HGC 
levels. However, it seems that it was not associated with 
abnormal prenatal screening test results. There might be 
a need for readjusting the risk in patients who received pro-
gesterone treatment in the early pregnancy. Large sample 
sizes, double-blind and randomized controlled trials are 
needed to detect the exact effects of progesterone on fetal 
screening tests.
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